Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.

about

Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.

Item

http://www.wikidata.org/entity/Q39074316

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@en

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@nl

type

Item

label

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@en

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@nl

prefLabel

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@en

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@nl

P1476

Granulocyte colony-stimulating ...... of cost-effectiveness models.

@en

P2093

Anju Parthan

http://www.w3.org/2001/XMLSchema#string

Gary H Lyman

http://www.w3.org/2001/XMLSchema#string

Guillermo Villa

http://www.w3.org/2001/XMLSchema#string

Kelly Fust

http://www.w3.org/2001/XMLSchema#string

Michael Maschio

http://www.w3.org/2001/XMLSchema#string

Qing Gu

http://www.w3.org/2001/XMLSchema#string

Spiros Tzivelekis

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Li

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-response effect of adjuvant chemotherapy in breast cancer

Colony-stimulating factors and peripheral blood progenitor cell transplantation. Benefits and costs.

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Cost effectiveness of treatment options in advanced breast cancer in the UK.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

P304

39-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737167.2017.1276829

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Milton Weinstein

P577

2017-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28064553

http://www.w3.org/2001/XMLSchema#string